Phase-III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - Study AP 118/21 of the AUO
UROLOGE（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要